Will launch three biosimilars globally in two-three years

Biocon Biologics (BBL), a subsidiary of Biocon, had refinanced $1.1 billion (₹9,300 crore) debt last month. The company's managing director and chief executive officer, SHREEHAS TAMBE, spoke to Sanket Koul and Aneeka Chatterjee in a video interview on issues ranging from refinancing, launches, and the road map. Edited Excerpts:

- SHREEHAS TAMBE

With the successful refinancing of long-term debt of $1.1 billion, how does BBL plan to leverage it? One of the important developments of this quarter is the strategic refinancing of our long-term debt through a $800 million bond issuance and a new syndicated long-term loan facility of $300 million. We had taken on this debt to support the transformational acquisition which moved us from being a Science and Operations led company to becoming a fully integrated global biosimilars organisation, which now has its presence in over 120 countries. That debt needed to be refinanced for greater financial liquidity so that we could re-deploy investments into the business to fuel growth. The refinancing will now help us focus on growing the business, without worrying about the quarter-by-quarter debt-to-EBITDA ratio or servicing of the debt beyond paying off the interest.

Do you have any launches lined up in the coming quarters?